Recent Company News

• 05:41 AM ET Oct 08, 2026
  

  Sino Biopharmaceutical completes enrollment in phase III registrational clinical trial of TQC3721 for COPD (HK$5.49, 0.00)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 10:50 PM ET Sep 20, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:23 PM ET Sep 28, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +1.12%; Hang Seng Futures +0.11%

• 02:00 PM ET Sep 28, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 21-Sep

• 04:53 AM ET Sep 28, 2026
  

  Sino Biopharmaceutical unit Chia Tai Tianqing signs strategic partnership agreement with STADA for pembrolizumab biosimilar (HK$5.50, 0.00)

• 10:03 AM ET Sep 21, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 19-Sep

• 11:34 PM ET Sep 20, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 09:18 PM ET Sep 15, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (1.14%); Hang Seng Futures (0.09%)